Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of BILR 355 BS Plus Low Dose Ritonavir in HIV-uninfected Male Volunteers

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Study to determine the safety, tolerability and pharmacokinetics of BILR 355 BS plus low dose ritonavir in healthy male volunteers.

Phase 1

Boehringer Ingelheim

Ritonavir